Carl Harald Jansonm, lead investment manager on the International Biotechnology investment trust, looks at how the sector has fared following the most recent sell-off
The US biotechnology sector’s stupendous bull run went into sharp reverse in August when the NASDAQ biotechnology index plunged by more than 20% from its peak value in July, before recovering. The...
Marcus Brookes appointed CIO
Industry Voice: Over the past ten years, investors have operated in an environment characterised by extremely accommodative and unconventional monetary policy.
Latest news and analysis
Aviva Investors' chief investment officer for equities, David Cumming, discusses how his team have integrated ESG factors into their decision-making process